Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,156 GBX | -0.12% | +7.88% | +14.68% |
May. 02 | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
May. 02 | AstraZeneca: research into respiratory diseases | CF |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- AZN Stock
- Revisions AstraZeneca PLC